The short answer
The added bleeding risk from ginger root powder with ticagrelor is uncertain. Review the exact product, dose and your bleeding history with your prescriber.
What this answer covers
Oral ginger root powder with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
- Supplement or preparation
- Zingiber Officinale (Ginger) Root Powder
- Medication ingredient
- ticagrelor
What the evidence shows
Human studies of dried or powdered ginger have produced dose-dependent results. A small single-dose 2 g study and a 4 g daily study found no significant measured platelet effect, whereas a separate 10 g dose inhibited aggregation. These were laboratory findings, not proof of bleeding from this combination.
Consider the prescribed treatment
Ticagrelor reduces platelet activity and can cause serious bleeding. The label also warns that stopping it increases cardiovascular risk, including stent-related harm in relevant patients. Have your prescribing team review supplements and procedure plans; do not stop ticagrelor or assume that a few hours of spacing removes a possible bleeding concern.
Review the exact product
Record the grams of root powder, frequency and other ingredients. Concentrated extracts, fresh ginger and culinary use are not identical to the preparations studied. No tested dose has been established as universally safe or harmful with this prescription medicine.
Know when to get help
Seek urgent care for bleeding that will not stop, vomiting blood or black, tarry stools. Tell your prescriber about the full supplement and medicine list. Do not stop prescribed antiplatelet treatment on your own to accommodate a supplement; ask the treating team to make a plan.
Evidence and practical considerations
Side effects & toxicity
An increased bleeding rate specifically from ginger root powder with ticagrelor has not been established.
- Exact scope
- Oral ginger root powder with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable. with Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.
- Medication form and route
- Oral
What remains uncertain
- Available supplement-only and other-drug studies do not establish exact-pair clinical harm or exclude rare events. No validated preventive spacing interval.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Prescription oral oral ticagrelor tablets users; short human pharmacology studies where described.
Significant bleeding risk; stopping treatment raises cardiovascular risk. Strong CYP3A inducers lower exposure and efficacy and should be avoided.
How this applies: Exact current product label. Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.
No exact botanical bleeding rate. Rifampin exposure changes are not an effect size for St. John’s wort.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients with coronary artery disease in the ginger component of a controlled study.
Repeated 4 g daily did not change measured platelet aggregation; the single 10 g dose inhibited aggregation to two agonists.
How this applies: Indirect for oral ticagrelor tablets co-use; exact preparation and endpoint retained.
Abstract-only; platelet endpoint, not clinical bleeding. Background regimen detail incomplete; cannot attribute an exact NSAID interaction.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Eight healthy male volunteers.
No difference in bleeding time, platelet count, thromboelastography or measured aggregation.
How this applies: Indirect for oral ticagrelor tablets co-use; exact preparation and endpoint retained.
Abstract-only, very small and single-dose. No exact drug combination or universal safe dose established.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
ticagrelor is IN.
How this applies: Exact identity.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 2026d43e6cb535a9
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.